[{"id":"0d61524a-ac9d-4310-9ed1-109db1699bfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05058352","created_at":"2021-09-27T12:53:06.831Z","updated_at":"2024-07-02T16:36:23.912Z","phase":"Phase 1","brief_title":"A Study of HS269 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05058352","lead_sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HS269"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2021-09-27"}]